Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Deborah Bykowski

Registered Nurse, Psychiatric/Mental Health, Adult Carmel, IN Nurse Practitioner

NPI 1366883498 CMS profile 11245054

703 Pro-Med Ln, Carmel, IN 46032

Open in the dashboard

General payments

$2,685

106 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Deborah Bykowski of Carmel, IN is reported in the CMS Open Payments database as having received $2,685 across 106 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Registered Nurse, Psychiatric/Mental Health, Adult profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $692 24
2024 General $855 32
2023 General $1,023 43
2022 General $96 6
2021 General $19 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Deborah Bykowski
  • Registered Nurse, Psychiatric/Mental Health, Adult median
  • Middle half of Registered Nurse, Psychiatric/Mental Health, Adult
  • National median

In program year 2025, general payments to Deborah Bykowski were reported at $692. Among 96 Registered Nurse, Psychiatric/Mental Health, Adult profiles paid that year, the median was $121 and the middle half received between $39 and $265.

Show as a table
Year Deborah Bykowski Registered Nurse, Psychiatric/Mental Health, Adult median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $19 $108 $31–$328 $132
2022 $96 $99 $22–$306 $149
2023 $1,023 $99 $43–$313 $160
2024 $855 $119 $30–$319 $164
2025 $692 $121 $39–$265 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $488 22 payments
  2. Teva Pharmaceuticals USA, Inc. $415 13 payments
  3. Vanda Pharmaceuticals Inc. $329 9 payments
  4. Neurocrine Biosciences, Inc. $257 8 payments
  5. Axsome Therapeutics, Inc. $203 7 payments
  6. Ironshore Pharmaceuticals Inc. $177 6 payments
  7. ITI, Inc. $161 9 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $146 8 payments
  9. Supernus Pharmaceuticals, Inc. $125 1 payment
  10. Corium, Inc. $112 8 payments
  11. Other $271 15 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,462 104 payments
  2. Education $223 2 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR $426 18 payments
  2. FANAPT $329 9 payments
  3. INGREZZA $257 8 payments
  4. HETLIOZ $210 8 payments
  5. Auvelity $178 5 payments
  6. JORNAY PM $177 6 payments
  7. CAPLYTA $146 8 payments
  8. TRINTELLIX $146 8 payments
  9. QELBREE $125 1 payment
  10. Austedo XR $117 6 payments
  11. Other $627 39 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

287

Median for Registered Nurse: 109

Drug cost

$31,928

Median for Registered Nurse: $4,454

Branded share of claims

25.8%

Median for Registered Nurse: 15.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 20 $28,512
Bupropion Xl Bupropion Hcl Brand 25 $866
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 29 $810
Clonazepam Generic 20 $324
Paroxetine Hcl Generic 15 $272
Lurasidone Hcl Generic 13 $211
Buspirone Hcl Generic 29 $178
Alprazolam Generic 53 $175
Gabapentin Generic 13 $168
Hydroxyzine Pamoate Generic 12 $162

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 476 Part D prescribers listed as Registered Nurse; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $191
$191 20 —
CAPLYTA
  • ITI, Inc. $93
$93 — —
TRINTELLIX
  • Takeda Pharmaceuticals U.S.A., Inc. $88
$88 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $51
$51 — —
FANAPT
  • Vanda Pharmaceuticals Inc. $47
$47 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

106 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Registered Nurse, Psychiatric/Mental Health, Adult in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record